Skip to main content
Condition

Peripheral Neuropathy Treatment

Peripheral neuropathy is not a single disease. It is the final common pathway of dozens of distinct metabolic, inflammatory, and toxic insults to nerve fibers. Standard neurology often stops at the symptom—prescribing gabapentin and calling it managed. We start with the mechanism, identify the specific cause, and build a treatment protocol around what that nerve actually needs to repair.

Schedule a ConsultationCall (912) 268-3097

The Neurology of Peripheral Neuropathy

Peripheral nerves carry motor, sensory, and autonomic signals between the spinal cord and the rest of the body. When those fibers are injured, the clinical picture depends on which fiber types are affected and how the damage occurs. The distinction matters because the treatment implications are entirely different.

Axonal neuropathies involve direct damage to the nerve fiber itself. The axon degenerates from the terminal end backward toward the cell body—a process called Wallerian degeneration. This is the pattern seen in most diabetic neuropathies, toxic exposures, and many metabolic deficiency states. Feldman et al. (2019, The Lancet Neurology) described the central role of mitochondrial dysfunction and oxidative stress in diabetic axonal injury, demonstrating that hyperglycemia damages the mitochondrial electron transport chain in dorsal root ganglion neurons long before structural nerve changes appear on electrodiagnostic testing.

Demyelinating neuropathies affect the myelin sheath that insulates nerve fibers. When myelin is stripped or damaged, conduction velocity slows and signals scatter. Chronic inflammatory demyelinating polyneuropathy and its variants represent the classic immune-mediated examples, but subtler demyelinating patterns also appear in nutritional deficiencies and certain toxic exposures.

Small fiber neuropathy deserves particular attention because it is the most commonly missed diagnosis in clinical neurology. These thinly myelinated A-delta and unmyelinated C fibers carry pain, temperature, and autonomic signals. When they degenerate, patients develop burning pain, prickling sensations, and autonomic symptoms including temperature dysregulation, gastroparesis, and orthostatic intolerance. Staff and Windebank (2003, Annals of Neurology) established skin punch biopsy with intraepidermal nerve fiber density quantification as the diagnostic standard for small fiber neuropathy—a test that most neurology practices still do not perform routinely.

Why Standard Evaluation Often Falls Short

The conventional neurology workup for neuropathy follows a predictable sequence: nerve conduction study, electromyography, basic blood work, and a prescription. If the EMG and NCS are normal, the patient is frequently told that their nerves are fine. This conclusion is wrong in a substantial number of cases.

EMG and NCS measure the electrical function of large myelinated nerve fibers. They are excellent tools for what they were designed to detect—carpal tunnel syndrome, ulnar neuropathy at the elbow, demyelinating polyneuropathies. But they are structurally incapable of assessing small fiber function. A patient with severe small fiber neuropathy can have completely normal nerve conduction studies. Devigili et al. (2008, Brain) demonstrated that clinical criteria combined with skin biopsy identified small fiber neuropathy in patients whose electrodiagnostic studies were entirely unremarkable.

The metabolic workup is often equally incomplete. Standard panels check fasting glucose and sometimes HbA1c. They frequently omit methylmalonic acid, which detects functional B12 deficiency before serum B12 levels drop below the laboratory reference range. Copper, zinc, folate, and inflammatory markers are rarely ordered. Neurogenomic panels that identify variants in methylation pathways, detoxification enzymes, and mitochondrial function genes are almost never part of the initial evaluation.

The result is a large population of patients carrying a diagnosis of “idiopathic neuropathy”—a label that means we stopped looking before we found the cause. Published data suggest that up to 30% of neuropathies initially classified as idiopathic have an identifiable etiology when the workup is expanded (Dyck et al., 2000, Annals of Neurology).

Specific Types We Evaluate & Treat

Diabetic neuropathy is the most prevalent form worldwide and the leading cause of nontraumatic amputation. The injury begins at the level of the mitochondria in dorsal root ganglion neurons, where hyperglycemia-induced oxidative stress overwhelms the cell’s antioxidant defenses. The downstream effects include axonal degeneration, Schwann cell dysfunction, and microvascular ischemia that progressively starves nerve tissue of oxygen and nutrients. Treatment must address the metabolic root—not merely manage blood glucose.

Chemotherapy-induced peripheral neuropathy affects up to 70% of patients treated with platinum-based agents like cisplatin, taxanes such as paclitaxel, and vinca alkaloids. These drugs damage dorsal root ganglion neurons through direct mitochondrial toxicity and disruption of axonal transport. Staff et al. (2017, Annals of Neurology) documented persistent intraepidermal nerve fiber loss years after chemotherapy completion, confirming that this is not simply a transient side effect but a lasting structural injury.

Post-viral neuropathies have become more visible since COVID-19, though they are not new. Epstein-Barr virus, herpes zoster, HIV, and hepatitis C have long been recognized as causes of peripheral nerve damage. SARS-CoV-2 adds to this list through both direct viral neurotropism and a sustained inflammatory response that damages small fibers and autonomic nerves. Patients present with burning pain, dysautonomia, and sensory disturbances that frequently persist for months after the acute infection resolves.

Idiopathic small fiber neuropathy is the label given when no cause is found on initial workup. In our experience, expanding the diagnostic evaluation to include autoimmune panels, neurogenomic profiling, and metabolic markers beyond the standard panel frequently reveals a treatable driver that was simply never tested for.

Treatment Approach

Once the specific mechanism of nerve injury is identified, we build a protocol from therapies that target mitochondrial recovery, oxidative protection, and cellular repair.

NAD+ IV Therapy

Restores mitochondrial function in metabolically stressed neurons and Schwann cells. NAD+ is the central coenzyme in oxidative phosphorylation and a required substrate for PARP-1 and sirtuin enzymes involved in DNA repair and cellular stress responses.

Glutathione IV Therapy

The primary intracellular antioxidant defending peripheral nerve tissue against reactive oxygen species. Glutathione depletion is a documented mechanism in both diabetic and chemotherapy-induced neuropathy.

Stem Cell Therapy

Mesenchymal stem cells release neurotrophic factors including nerve growth factor and brain-derived neurotrophic factor that support Schwann cell proliferation, axonal regrowth, and remyelination.

Exosome Therapy

Extracellular vesicles carrying anti-inflammatory cytokines, microRNAs, and growth factors that modulate the local immune response at sites of nerve injury and support tissue regeneration.

Myers’ Cocktail IV

Delivers magnesium, B-complex vitamins, calcium, and vitamin C intravenously to correct nutritional deficiencies that contribute to nerve dysfunction and impair the cellular machinery needed for repair.

Our Diagnostic Approach

Every neuropathy evaluation at The Neurogenesis Project begins with a detailed clinical history and neurological examination, followed by a diagnostic workup designed to identify the specific mechanism of nerve injury—not simply confirm that neuropathy is present.

Nerve conduction studies and electromyography assess the function of large myelinated motor and sensory fibers. These tests quantify conduction velocity, amplitude, and latency to determine whether the pattern is axonal, demyelinating, or mixed—and whether the distribution is symmetric, asymmetric, or multifocal. This information narrows the differential diagnosis substantially.

Skin punch biopsy with intraepidermal nerve fiber density quantification is performed when small fiber neuropathy is suspected. This test directly measures the density of small sensory nerve endings in the epidermis and is the most sensitive and specific diagnostic tool for small fiber neuropathy available today.

Comprehensive metabolic and inflammatory panels go well beyond standard blood work. We measure HbA1c, fasting insulin, vitamin B12 with methylmalonic acid, folate, copper, zinc, erythrocyte sedimentation rate, C-reactive protein, antinuclear antibodies, and in selected cases, paraneoplastic antibody panels and ganglioside antibodies. These labs identify metabolic, nutritional, inflammatory, and autoimmune causes that are frequently missed on initial evaluation.

Neurogenomic panels evaluate genetic variants in methylation pathways (MTHFR, COMT, CBS), detoxification enzymes, and mitochondrial function genes. These variants do not cause neuropathy on their own, but they influence how a given patient metabolizes nutrients, clears toxins, and responds to oxidative stress—all of which affect nerve health and treatment response.

Autonomic testing is added when patients report symptoms such as orthostatic intolerance, abnormal sweating, gastroparesis, or temperature dysregulation. Autonomic neuropathy often accompanies small fiber disease and requires its own diagnostic confirmation.

Related Treatments

NAD+ IV Therapy

Restore mitochondrial energy production in neurons and Schwann cells under metabolic stress. NAD+ is the primary substrate for oxidative phosphorylation and a required cofactor for DNA repair enzymes critical to nerve cell survival.

Glutathione IV Therapy

Replenish the body’s primary intracellular antioxidant to protect peripheral nerve tissue from reactive oxygen species generated by mitochondrial dysfunction, hyperglycemia, and chemotherapeutic agents.

Stem Cell Therapy

Mesenchymal stem cells deliver neurotrophic factors to damaged peripheral nerves, support Schwann cell function, modulate local inflammation, and promote the axonal regrowth and remyelination needed for functional recovery.

Frequently Asked Questions

What types of peripheral neuropathy do you treat?+
We evaluate and treat the full spectrum of peripheral neuropathies. This includes diabetic neuropathy, chemotherapy-induced peripheral neuropathy from agents like cisplatin and paclitaxel, idiopathic small fiber neuropathy, post-viral neuropathies following infections such as COVID-19 or herpes zoster, inflammatory and autoimmune neuropathies, nutritional deficiency neuropathies related to B12 or copper depletion, and hereditary neuropathies. Our diagnostic workup is designed to identify the specific mechanism driving each patient's nerve injury rather than grouping all neuropathies into a single treatment plan.
How is your diagnostic approach different from a standard neurology evaluation?+
Most neurology offices evaluate neuropathy with a nerve conduction study and electromyography. If those results are normal, the patient is often told their nerves are fine. The problem is that EMG and NCS primarily assess large myelinated nerve fibers. They miss small fiber neuropathy entirely, which accounts for a significant percentage of patients with burning pain, numbness, and autonomic symptoms. We supplement electrodiagnostic testing with skin punch biopsy for intraepidermal nerve fiber density, comprehensive metabolic panels including HbA1c, vitamin B12, methylmalonic acid, folate, copper, and zinc levels, inflammatory markers, and neurogenomic panels that identify genetic variants affecting nerve repair and metabolism.
Can peripheral nerve damage actually be reversed?+
Peripheral nerves have a regenerative capacity that central nervous system neurons lack. The extent of recovery depends on the type of injury, its duration, the underlying cause, and individual biology. Axonal neuropathies where the nerve fiber itself is damaged can regenerate at roughly one millimeter per day if the metabolic environment supports repair. Demyelinating neuropathies, where the insulating sheath is damaged but the axon remains intact, can recover more quickly once the inflammatory or metabolic driver is controlled. The critical variable is identifying and correcting the root cause early, then providing the cellular support the nerve needs to rebuild.
What treatments do you use for neuropathy?+
Our protocols are built around each patient's specific diagnosis. NAD+ intravenous therapy restores mitochondrial function in metabolically stressed neurons and Schwann cells. Glutathione IV therapy provides antioxidant protection against the oxidative damage that drives many forms of neuropathy, particularly chemotherapy-induced and diabetic types. Mesenchymal stem cell therapy and exosome therapy deliver trophic factors and anti-inflammatory signals that support nerve fiber regrowth. These therapies are combined based on diagnostic findings and delivered during our Intensive Brain Health Program over three to five consecutive days.
How long does treatment take and when will I notice improvement?+
The initial treatment is delivered during our Intensive Brain Health Program, which runs three to five consecutive days. Because peripheral nerve regeneration is a slow biological process, measurable improvement in symptoms typically develops over weeks to months following treatment. Some patients notice early changes in pain levels or sensation within two to four weeks. Others require follow-up infusion cycles at intervals of four to eight weeks. We track progress with repeat nerve conduction studies, symptom inventories, and in some cases repeat skin biopsy to measure nerve fiber density changes objectively.
Does insurance cover neuropathy treatment at your clinic?+
The Neurogenesis Project operates outside of insurance networks. Our diagnostic and treatment protocols use therapies that are not typically covered by commercial insurance plans or Medicare. We provide detailed superbills and medical documentation that patients can submit to their carriers for potential out-of-network reimbursement. Some diagnostic components, such as nerve conduction studies and certain blood panels, may be eligible for partial coverage. Our patient coordinator can discuss costs, payment plans, and documentation options before you schedule.

Stop Managing Symptoms. Start Treating the Cause.

If you’ve been told your nerve study is normal but your feet are still burning, or if you’re taking gabapentin and nothing has changed, the problem is not that treatment doesn’t exist. The problem is that no one has identified what your nerves actually need. Dr. Orr and the team at The Neurogenesis Project are evaluating neuropathy patients in St. Marys, Georgia.

Schedule Your Evaluation(912) 268-3097